2010消化道肿瘤（英文）.pptVIP

* * * * * * * * * * * * * * * * * Slide 14, RADIANT-1: although numbers are small, one might argue that these data are more supportive of octreotide LAR (in line with the PROMID data, slide 12) than of everolimus? I agree, this is indeed a complex study. I have made a small change to the study design box to make it clearer that assignement to octreotide LAR was only driven by the treatment ongoing at the moment of study entry. The (apparently) longer PFS in stratum 2 may thus be the product not only of large confidence-limits due to the small sample size, but also of potential differences i